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Abstract
The size of von Willebrand factor (VWF), controlled by ADAMTS13-dependent proteolysis, is associated with its hemostatic
activity. Many factors regulate ADAMTS13-dependent VWF proteolysis through their interaction with VWF. These include
coagulation factor VIII, platelet glycoprotein 1ba, and heparin sulfate, which accelerate the cleavage of VWF. Conversely,
thrombospondin-1 decreases the rate of VWF proteolysis by ADAMTS13 by competing with ADAMTS13 for the A3 domain
of VWF. To investigate whether murine monoclonal antibodies (mAbs) against human VWF affect the susceptibility of VWF
to proteolysis by ADAMTS13 in vitro, eight mAbs to different domains of human VWF were used to evaluate the effects on
VWF cleavage by ADAMTS13 under fluid shear stress and static/denaturing conditions. Additionally, the epitope of anti-VWF
mAb (SZ34) was mapped using recombinant proteins in combination with enzyme-linked immunosorbent assay and
Western blot analysis. The results indicate that mAb SZ34 inhibited proteolytic cleavage of VWF by ADAMTS13 in a
concentration-dependent manner under fluid shear stress, but not under static/denaturing conditions. The binding epitope
of SZ34 mAb is located between A1555 and G1595 in the central A2 domain of VWF. These data show that an anti-VWF mAb
against the VWF-A2 domain (A1555-G1595) reduces the proteolytic cleavage of VWF by ADAMTS13 under shear stress,
suggesting the role of this region in interaction with ADAMTS13.
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Introduction
Plasma von Willebrand factor (VWF) is a large multimeric
glycoprotein that interacts with platelet surface receptors and
is crucial for normal hemostasis. The adhesive activity of
VWF is positively correlated with the size of the multimers in
plasma [1,2]. VWF multimer size is regulated by metalloprotei-
nase ADAMTS13, which cleaves the central A2 domain of VWF
at the Tyr1605-Met1606 bond [3–4]. The importance of VWF
proteolysis by ADAMTS13 is demonstrated in two syndromes, i.e.,
thrombotic thrombocytopenic purpura and von Willebrand
disease type 2A. The former is associated with the deficiency of
plasma ADAMTS13 activity, either due to congenital mutations
or acquired autoantibodies [5–7]. The latter is mostly caused by
mutations in the A2 domain of VWF that lead to the increased
proteolysis of VWF multimers by ADAMTS13 [8,9].
Many factors modulate the proteolysis of VWF by ADA-
MTS13. These ligands that bind the A1 domain of VWF such as
platelet glycoprotein Iba, heparin and ristocetin promote VWF
proteolysis by ADAMTS13 [10]. In addition, platelets also signifi-
cantly enhance the cleavage of VWF multimers by ADAMTS13
underfluidshearstress[11,12].Onthecontrary,thrombospondin-1,
an extracellular matrix adhesion protein, may compete with
ADAMTS13 for binding to the A3 domain of VWF, which reduces
the rate of VWF proteolysis by ADAMTS13 [13,14].
In this study, we investigated the effects of eight murine mono-
clonal antibodies (mAbs) against various domains of VWF on its
proteolysis by ADAMTS13 under physiologically relevant condi-
tions. Among those, mAb SZ34 dramatically decreased the suscepti-
bility of VWF to ADAMTS13 under shear stress, but not under
static/denaturing conditions. The epitope of SZ34 was mapped to
the amino acid residues between A1555 and G1595 in the central
A2 domain of VWF. Our findings highlight the critical role of this
region for ADAMTS13-mediated proteolysis under shear stress.
Results
Anti-VWF mAb SZ34 decreases the susceptibility of VWF
to proteolysis by ADAMTS13 under shear stress
In this study, we used rADAMTS13 and pVWF as the sources
of enzyme and substrate to determine the effect of SZ34 on VWF
proteolysis under shear stress. The cleavage product was deter-
mined by SDS-PAGE under non-reducing conditions followed
by Western blot. The results showed that the 350 kDa cleavage
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22157product of VWF under shear stress was reduced in the presence of
SZ34 in a concentration-dependent manner (Figure 1). The half
maximal (50%) inhibitory concentration (IC50) of the SZ34 was
estimated to be approximately 50 mg/ml (Figure 1). In contrast,
other anti-VWF mAbs including 1C1E7 (an anti-VWF D’D3
mAb), SZ129 (an anti-VWF A1 mAb), SZ123 (an anti-VWF A3
mAb) and so on had no effects on the proteolytic cleavage of VWF
by ADAMTS13 (Figure 1 and Table 1). The control experiments
established the lack of detectable proteolysis in the absence of
ADAMTS13 or in the addition of 20 mM EDTA to reaction
mixtures (Figure 1).
The proteolysis of VWF by ADAMTS13 in the absence and
presence of anti-VWF mAbs was also determined by agarose gel
electrophoresis visualizing VWF multimers. We showed that the
decreased amount of the high and intermediate molecular weight
multimers were dramatically reduced by mAb SZ34 in a con-
centration-dependent manner under shear stress (Figure 2), further
confirming the role of SZ34 in decreasing the susceptibility of
VWF to proteolytic cleavage by ADAMTS13 under physiologi-
cally relevant conditions.
SZ34 had no effects on VWF proteolysis by ADAMTS13
under denaturing/static condition
When pVWF was pre-denatured with guanidine-HCl before
incubation with SZ34 and rADAMTS13, no obvious difference
in the 350 kDa cleavage products was detected (Figure 3 and
Figure 1. SZ34 inhibits the proteolytic cleavage of pVWF by rADAMTS13 under shear stress. (A) Purified pVWF (150 nM) was pre-
incubated with SZ34 (0–200 mg/ml) for 30 min at 37uC, and then incubated with 50 nM rADAMTS13. After 5 min of vortexing at 2,500 rpm on a mini
vortexer, the 350 kDa cleavage products were visualized by 5% SDS-PAGE under non-reducing conditions and Western blot analysis. 1C1E7 (an anti-
VWF D’D3 mAb), SZ129 (an anti-VWF A1 mAb) and SZ123 (an anti-VWF A3 mAb) were used as negative controls. (B) Changes in the cleavage products
detected relative to that observed in the absence of mAbs were determined under shear stress by densitometry. The extent of cleavage was analyzed
by detection of the intensity of the 350 kDa cleavage products. Results represent the mean 6 standard deviation of four independent experiments.
doi:10.1371/journal.pone.0022157.g001
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VWF by ADAMTS13. In the meantime, anti-VWF mAbs
including 1C1E7, SZ129, SZ123, etc, exhibited no effects on
ADAMTS13-mediated proteolysis of the unfolded VWF under
static conditions either (Figure 3 and Table 1).
To exclude the influence of denaturing condition on interaction
between VWF and antibodies, we constructed and expressed
VWF-R1597W mutant and investigated whether SZ34 inhibited
its proteolysis by ADAMTS13. R1597W is the most frequent
mutation in von Willebrand disease type 2A and the mutation site
is adjacent to Tyr1605-Met1606 bond. This mutant VWF can be
cleaved by ADAMTS13 under static condition and in the absence
of denaturants such as urea and guanidine [8]. The results showed
that with or without SZ34 R1597W VWF multimers were equally
effectively cleaved by ADAMTS13 under static conditions
(Figure 4), which suggested that SZ34 had no effects on the
proteolysis of this VWF mutant by ADAMTS13. Preliminary
experiments have shown that SZ34 binds to VWF- R1597W
multimers by an ELISA method and the dissociation constants
(Kd) is 0.6760.11 nM.
Epitope mapping of anti-VWF mAb SZ34
To determine the binding epitope of SZ-34, we prepared a
series of recombinant VWF fragments, including A1A2A3, A1,
A2, A3 and D’D3 (Figure 5A), and five GST fusion VWF-A2
fragments, i.e. A2-1, A2-2, A2-3 (VWF73), A2-12 and A2-23
(VWF114) (Figure 5B). We measured the binding capacities
(dissociation constants, Kd) of SZ34 to native and guanidine-
denatured VWF and various VWF fragments by ELISA method.
SZ34 bound to native and pre-denatured full-length VWF,
A1A2A3, and A2, but only native A2-12 and A2-23 (Table 2).
Furthermore, the binding of SZ34 to the pre-denatured VWF and
VWF fragments was much weaker than the native counterparts
(Table 2). These data suggest that the epitope of SZ34 is
conformationally sensitive. The binding site was mapped to the
central A2 domain of VWF. Because SZ34 bound to both native
A2-12 and native A2-23, the epitope of SZ34 appeared to be
located within the A2-2 (A1555-G1595 region).
To further to testify that SZ34 is a conformational mAb against
VWF, a western blot in combination with ELISA based on
polystyrene microspheres was performed to compare the binding
activities of SZ34 to native pVWF and denatured pVWF.
Compared with native pVWF, the binding activity of SZ34 to
heated pVWF or pVWF treated with 1.5 M guanidine-HCl was
significantly reduced (Figure 6), further confirming that SZ34 is a
conformation-sensitive mAb to VWF.
Discussion
We found that SZ34, a mAb against the A2 domain of human
VWF, reduces the susceptibility of VWF to proteolysis by
ADAMTS13 under fluid shear stress. However, this effect was
not observed under static and chemically denaturing conditions.
Seven other mAbs against VWF including SZ129 and SZ130 (two
mAbs against VWF A1), SZ29 (another mAb against VWF A2),
SZ123 and SZ125 (two mAbs against VWF A3) and 1C1E7 and
75H4B12 (two mAbs against VWF D’D3) exhibited no effects on
ADAMTS13-mediated VWF proteolysis under either shear stress
or denaturing conditions. The epitope mapping shows that the
epitope of SZ-34 is located within the A1555-G1595 region of the
A2 domain of native VWF, suggesting that this region may directly
interact with ADAMTS13. Furthermore, the mAb SZ-34 is a
conformation-sensitive mAb because it preferentially binds to
native VWF.
Table 1. Summary of 8 mAbs to VWF and their effects on VWF proteolysis by ADAMTS13.
mAbs Epitope Effects on VWF proteolysis by ADAMTS13
under shear stress under static/denaturing conditions
1C1E7
25 VWF-D’D3 no effect no effect
75H4B12
25 VWF-D’D3 no effect no effect
SZ129
26 VWF-A1 no effect no effect
SZ130
26 VWF-A1 no effect no effect
SZ29
28 VWF-A2 no effect no effect
SZ34
27,28 VWF-A2 inhibition no effect
SZ123
27 VWF-A3 no effect no effect
SZ125
27 VWF-A3 no effect no effect
doi:10.1371/journal.pone.0022157.t001
Figure 2. SZ34 inhibits the proteolysis of VWF multimers by
ADAMTS13 under shear stress. Purified pVWF (150 nM) was pre-
incubated with SZ34 (0–200 mg/ml) for 30 min at 37uC, and then
incubated with 50 nM rADAMTS13. After 5 min of vortexing at
2,500 rpm on a mini vortexer, VWF multimers were separated by
1.5% agarose gel electrophoresis and immunologic analysis. A
representative image of 4 independent experiments is shown.
doi:10.1371/journal.pone.0022157.g002
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bitory effects of VWF antibodies on the proteolysis of VWF by
ADAMTS13, but the mechanism of inhibition by SZ34 may be
different from that of the two other mAbs VP-1 and RU8 reported
by Tsai et al [15] and Zanardeli et al [16], respectively. The mAb
VP-1, which was directly against residues 1591–1605 (inside VWF
A2 domain) of VWF polypeptide, inhibited the susceptibility of the
recombinant type 2A VWF mutants R1606W and R1606Q to
proteolytic cleavage by ADAMTS13 under the static condition.
But they did not examine whether VP-1 inhibited native pVWF or
wild-type recombinant VWF proteolysis by ADAMTS13 [15].
Because VP-1 was raised against the synthetic VWF peptide
(residues 1591–1605) and reacted poorly with the intact subunit
(250 kDa fragment) of VWF in reduced SDS-PAGE followed by
immunoblotting [3,15], we speculated that VP-1 could not bind to
native VWF and could not affect its proteolysis by ADAMTS13
without denaturization or under shear stress. In addition, Zanar-
delli et al [16] reported the inhibition of VWF proteolysis by
ADAMTS13 under shear by using RU8, a mAb directed against
the VWF D4 domain. They suggested that a binding site in the C-
terminal region (D4CK) of VWF is constitutively exposed and
participates at the initial step of a multi-step interaction, ultimately
leading to proteolysis of VWF by ADAMTS13. Thus, RU8 may
inhibit VWF proteolysis by inhibiting the initial binding of the
distal domains of ADAMTS13 to the C-terminal region of VWF.
We found that the mAb, SZ34, bound to native VWF better than
pre-denatured VWF at the central A2 domain, and decreased the
cleavage of native VWF under shear stress, but not pre-denatured
VWF under static conditions. These findings suggest that SZ34
binds native VWF-A2 domain, which may block the conforma-
tional change of VWF or block the access of ADAMTS13 to the
ancillary binding site and cleavage bond located at the central A2
domain under fluid shear stress.
The ADAMTS13 cleavage site (the Y1605-M1606 bond) in
the VWF A2 domain is buried within the native, folded structure
of VWF multimers and is not accessible to cleavage by the
metalloprotease [3–5]. Although a report found that recombinant
VWF-A2 peptide (a.a.1481–1668) was sensitive to proteolysis by
ADAMTS-13 under physiological pH and non-denaturing
conditions [17], most of studies have shown that even for the
isolated A2 domain, unfolding by high fluid shear stress or
chemical denaturants such as urea and guanidine-HCl is required
for proteolysis by ADAMTS13 [10,18]. Thus, for VWF with its
multi-domain structure, not only the inter-domain but also the
intra-domain A2 structural changes have regulatory roles in
ADAMTS13-mediated cleavage of VWF. Our data demonstrate
Figure 3. SZ34 has no effects on the proteolysis of denatured pVWF by rADAMTS13 under static conditions. (A) Purified pVWF
(150 nM) pretreated with guanidine-HCl was incubated with SZ34 (0–200 mg/ml), and then incubated with 25 nM rADAMTS13. After 1.5 h, the
reaction was quenched by adding 20 mM EDTA. The 350 kDa cleavage products were analyzed by Western blot as above. 1C1E7, SZ129 and SZ123
were used as controls. (B) Changes in the cleavage product detected relative to that observed in the absence of SZ34 were determined under
denatured conditions by densitometry. The extent of cleavage was analyzed by detection of the intensity of the 350 kDa cleavage products. Results
represent the mean 6 standard deviation of four independent experiments.
doi:10.1371/journal.pone.0022157.g003
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multimers, is located within the A1555-G1595 region, which
comprises the a2-helix and a3-helix according to the crystal
structure of VWF A2 domain [19]. It is possible that part or all of
the a2-helix and a3-helix structure of A2 domain is constitutively
exposed on the native VWF multimers and is involved in the
regulation of VWF proteolysis by ADAMTS13. Previous studies,
however, considered that the A2 domain of VWF is normally
sandwiched between the much larger A1 and A3 domains [19,20],
and the D1596-R1668 region in VWF A2 domain (the so called
VWF73) is the minimal substrate for ADAMTS13 [21].
We conclude that SZ34 is a conformationally sensitive anti-
VWF mAb which can modulate proteolytic cleavage of VWF
by ADAMTS13 under physiologically relevant conditions. This
monoclonal anti-VWF antibody may be a useful tool for further
investigating biological function of VWF in vivo.
Materials and Methods
Purification of plasma-derived VWF
Plasma-derived human VWF (pVWF) was purified from com-
mercial VWF/FVIII concentrate by gel filtration with a Sepharose
4B-CL column (Amersham Pharmacia Biotech AB, Uppsala,
Sweden) and heparin-Sepharose 6FF (Pharmacia) affinity chro-
matography, as reported [22]. VWF antigen (VWF:Ag) concen-
tration was determined by an enzyme-linked immunosorbent
assay (ELISA) kit from Dako (Glostrup, Denmark) and VWF
multimers analysis was performed as reported [23].
Recombinant human ADAMTS13
Plasmid ADAMTS13 containing human full-length cDNA
sequence was generously provided by Dr. Jingfei Dong (Baylor
College of Medicine, Houston, TX, USA) [24]. Recombinant
ADAMTS13 (rADAMTS13) with the C-terminal His-tag was
expressed in a stably transfected HeLa cell line. Expression medium
was concentrated and purified using a Ni-NTA agarose column
(QIAGEN GmbH, Hilden, Germany).
Antibodies to VWF
Eight murine mAbs against human VWF were used. The anti-
VWF D’D3 domain mAbs 1C1E7 and 75H4B12 were kind gifts
from Dr. Deckmyn (Laboratory for Thrombosis Research, KU
Leuven Campus Kortrijk, Kortrijk, Belgium) [25]. Others were all
previously produced in our laboratory. SZ129 and SZ130 recognize
VWF A1 domain [26], whereas SZ123 and SZ125 interact with
VWF A3 domain [27]. SZ29 and SZ34 are mAbs to VWF, whose
epitopes are indefinite because of being directly raised against
purified plasma-derived full-length human native VWF [27,28].
Horse-radish peroxidase (HRP)-conjugated polyclonal rabbit anti-
human VWF IgG was purchased from Dako (Glostrup, Denmark).
Cleavage of VWF by ADAMTS13 in the presence of
anti-VWF mAbs under shear stress
Purified pVWF (150 nM) in 20 mM Tris-HCl (pH 8.0), 0.15 M
NaCl, and 5 mg/ml (w/v) BSA was incubated separately with 8
Figure 4. SZ34 had no effect on proteolysis of VWF-R1597W
mutant by ADAMTS13. Recombinant VWF-R1597W (150 nM) was
incubated with 0 or 100 mg/ml SZ34 at 37uC for 30 min and then for
18 h with 25 nM rADAMTS13 at 37uC. VWF multimers were separated
by 1.5% agarose gel electrophoresis and immunologic analysis. A
representative image of 4 independent experiments is shown.
doi:10.1371/journal.pone.0022157.g004
Figure 5. Schematic domain structure of full-length VWF and
recombinant VWF fragments. The domain structure of human
preproVWF is shown above the structures ofrecombinant VWFfragments
designed in this study. ADAMTS-13 cleaves the Y1605-M1606 peptidyl
bond in the A2 domain (D1459-L1668). Five different recombinant VWF
domains with His-tags (Figure 5A) and 5 different recombinant proteins
derived from the VWF A2 domain flanked with GST- and His-tags
(Figure 5B).
doi:10.1371/journal.pone.0022157.g005
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25uC for 3 min with 50 nM rADAMTS13 that had been activated
by incubation with 5 mM CaCl2 in 20 mM Tris-HCl (pH 8.0),
0.15 M NaCl, and 5 mg/ml (w/v) BSA at 37uC for 1 h. The
mixture was then subjected to a mini vortexer (Fisher Scientific,
USA) with constant vortexing at 2,500 rpm for 5 min [23] and the
reaction was terminated by the addition of 20 mM EDTA.
Cleavage of VWF by ADAMTS13 in the presence of
anti-VWF mAbs under static/denaturing conditions
Purified VWF (1.5 mM) was pre-denatured with 1.5 M
guanidine-HCl in 20 mM Tris-HCl (pH 8.0) at 37uC for 2 h.
After a 1:10 dilution with 20 mM Tris-HCl (pH 8.0), the
denatured VWF was incubated with anti-VWF mAbs (0–
200 mg/ml) at 37uC for 30 min and then treated with 25 nM
rADAMTS13 that had been activated by incubation with 5 mM
CaCl2 at 37uC for 1 h. After incubation at 37uC for 1.5 h, the
reaction was stopped by the addition of 20 mM EDTA.
Expression of VWF-R1597W mutant and its cleavage by
ADAMTS13 in the presence of mAb SZ34 under static/
nondenaturing conditions
The plasmid PSVHvWF1, which harbors a full-length cDNA
insert of human VWF (kindly provided by JE Sadler, Washington
University School of Medicine, St Louis, USA) [29], was used to
construct the R1597W mutant by PCR-based single-nucleotide
mutagenesis. Recombinant VWF-R1597W mutant was expressed
in transiently transfected Hela cell line using serum-free OPTI-
MEM I (Invitrogen) for 48 h. The media were collected and added
into EDTA-free 16 proteinase inhibitor Cocktail (Roche), fol-
lowed by concentration using Amicon Ultra-15 Centrifugal Filter
(Millipore). VWF antigen (VWF:Ag) concentration was deter-
mined by an ELISA kit (Dako).
Recombinant VWF-R1597W (150 nM) was incubated with 0
or 100 mg/ml SZ34 at 37uC for 30 min and then for 18 h with
25 nM rADAMTS13 at 37uC.
Assessment of VWF proteolysis by SDS-PAGE and
agarose gel electrophoresis
The cleavage reactions were measured by the distribution of
proteolytic fragments (350 kDa) on a 5% SDS-PAGE under non-
reducing condition or by VWF multimeric size distribution on a
1.5% agarose gel electrophoresis, and then analyzed by West-
ern blotting with HRP-conjugated anti-VWF IgG (Dako) and
visualized by chemiluminescence as reported [23,30]. The inten-
sity of the bands was analyzed using Image J software.
Preparation of recombinant human VWF fragments
VWF D’D3 (S764P1247-H) expressed in BHK cells was a gift
from Dr. Deckmyn (Laboratory for Thrombosis Research, KU
Leuven Campus Kortrijk, Kortrijk, Belgium). The other recom-
binant VWF fragments including A1A2A3 (Q1238G1874-H), A1
(H-E1260P1467), A2 (H-G1481R1668), A3 (S1681R1877-H), A2-
12 (GST-D1459D1596-H), A2-23 (VWF114, GST-A1555R1668-
H), A2-1 (GST-D1459E1554-H), A2-2 (GST-A1555G1595-H)
and A2-3 (VWF73, GST-D1596R1668-H) were all expressed in
bacteria. Plasmids encoding different VWF fragments were all
generated from pSVHVWF1 [29].
Recombinant VWF D’D3, A1A2A3, A1, A2 and A3 all
contained a 66His tag (NOVAGEN, San Diego, CA, USA)
(Figure 5A). The preparation of VWF A1, A2 and A3 was described
previously [26,27,31]. Plasmid construction, expression and puri-
fication of VWF A1A2A3 were similar to VWF A3 [27]. Two
primers were used for amplifying VWF A1A2A3: 59-gga tcc GCA
GGAGCCGGGAGGC-39and59-ctcgagTCCAGAGCACAG
TTT GTG-39 (Lowercase letters for BamHI and XhoI sites). Four
recombinant VWF domains including A1A2A3, A1, A2 and A3
Table 2. Kinetics of SZ34 and SZ29 interactions with native or
denatured pVWF and various recombinant VWF fragments.
Various recombinant VWF
fragments or pVWF Kd (nM)
SZ34 SZ29
Native pVWF 4.7 (60.6)610
22 2.9 (60.4)610
22
Denatured pVWF 12.363.2 16.465.4
Native/denatured D’D3 (S764P1247) .10
3 .10
3
Native A1A2A3 (Q1238G1874) 0.9860.11 0.5160.03
Denatured A1A2A3 53.766.9 46.364.1
Native/denatured A1 (E1260P1467) .10
3 .10
3
Native A2 (G1481R1668) 5.260.8 3.360.5
Denatured A2 85.462.2 75.865.9
Native/denatured A3 (S1681R1877) .10
3 .10
3
Native A2-12 (D1459D1596) 38.465.9 62.468.3
Denatured A2-12 .10
3 .10
3
Native A2-23 (A15555R1668) 26.168.8 .10
3
Denatured A2-23 .10
3 .10
3
Native/denatured A2-1(D1459E1554) .10
3 .10
3
Native/denatured A2-2 (A1555G1595) .10
3 .10
3
Native/denatured A2-3 (D1596R1668) .10
3 .10
3
BSA .10
3 .10
3
Data represent mean 6 SD.
doi:10.1371/journal.pone.0022157.t002
Figure 6. Comparison of the binding activity of SZ34 to native
and denatured pVWF using Western blot in combination with
ELISA based on polystyrene microspheres. SZ34 (20 mg/ml) was
coated on polystyrene microspheres, then incubated with native pVWF
or denatured pVWF (100 nM). The denatured pVWF was obtained by
thermal treatment (20 min at 80uC) or treatment with 1.5 M guanidine-
HCl (2 h at 37uC) of native pVWF. Bound VWF was separated on 6%
SDS-PAGE in reducing conditions, followed by Western blotting with
SZ34. SZ129 (anti-VWF A1) was a control as a mAb with a linear epitope.
The figure is representative of four separate experiments.
doi:10.1371/journal.pone.0022157.g006
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refolding was achieved using an 8 to 0 M urea linear gradient.
Plasmids encoding A2-12, A2-23 (VWF114), A2-1, A2-2 and
A2-3 (VWF73) (Figure 5B) were constructed similarly in the GST
fusion vector pGEX-6P-1 (Amersham Biosciences, Piscataway, NJ).
These recombinant plasmids were prepared by use of primers as
follows: A2-12 (59-cgg gat cc GAC CTT GCC CCT GAA GCC
CCT C-39 and 59-cgg aat tc TCA GTG ATG GTG ATG GTG
ATGACCCTG GCTGACCAAGAAGCTG-39),A2-23(59-cgg
gat cc GCA CAGTCC AAA GGG GAC ATC C-39 and 59-cgg aat
tcTCA GTGATGGTGATGGTGATG CCTCTGCAGCAC
CAG GTC AGG A-39), A2-1 (59-cgg gat cc GAC CTT GCC CCT
GAA GCC CCT C-39 and 59-cgg aat tc TCA GTG ATG GTG
ATGGTGATGCTC GCTGAAGGGGTACTC CACAG-39),
A2-2 (59-cgg gat cc GCA CAG TCC AAA GGG GAC ATC C-39
and 59-cgg aat tc TCA GTG ATG GTG ATG GTG ATG ACC
CTG GCT GAC CAA GAA GCT G-39) and A2-3 (59-cgg gat cc
GAC CGG GAG CAG GCG CCC AAC C-39 and 9-cgg aat tc
TCA GTG ATG GTG ATG GTG ATG CCT CTG CAG CAC
CAG GTC AGG A-39). Lowercase letters indicateadded restriction
enzyme sites (BamHI and HindIII) and the underlined sequence was
the inserted C-terminal 66His-tag. The GST fusion proteins were
expressed and purified by chromatography on Ni-NTA agarose
(QIAGEN GmbH, Hilden, Germany) as described [21]. All five
recombinant GST fusion proteins were mainly expressed in soluble
fractions at low temperatures.
Unfolding of full-length VWF and VWF fragments for
epitope mapping of mAb SZ34
Heat treatment and denaturization treatment with guanidine-
HCl were used to unfold recombinant VWF fragments and pVWF.
Purified pVWF was denatured by heating at 80uC for 20 min in a
thermo-blockheater(ThermoStatPlus,Eppendorf)asreported[32].
Recombinant VWF fragments and pVWF were denatured with
guanidine-HCl [30] as following. Purified pVWF or various VWF
fragments (10 mM) were incubated with 1.5 M guanidine-HCl at
37uC for 2 h. Then, guanidine-HCl treated VWF fragments and
pVWF were diluted serially with 20 mM Tris-HCl (pH 8.0),
0.15 M NaCl. The binding affinity of denatured VWF and SZ34
was determined by an ELISA. Because the initial concentrations of
pVWF and VWF fragments were high, the final concentration of
guanidine-HCl in solution was ,20 mM, which did not interfere
with the binding activity of SZ34 (data not shown), consistent with
what was reported by Tsai [30] in which he showed that guanidine-
HCl at 24 mM did not interfere with the platelet aggregation.
Affinity measurements of SZ34 with full-length VWF and
various VWF fragments using ELISA
The native or denatured VWF fragments and pVWF at various
concentrations were first incubated in solution with the antibody
(SZ34 or SZ29) at constant concentration until equilibrium was
reached, respectively. The denatured VWF fragments and pVWF
were obtained by denaturization treatment with guanidine-HCl as
above. The concentration of free antibody was then determined by
an ELISA. The equilibrium dissociation constants (Kd) of
antigen/antibody complexes in solution were obtained according
to the equation [33]:
Kd~ 1{ A0{A ðÞ =A0 ½  = A0{A ðÞ =A0 ½  = a0{i0 A0{A ðÞ =A0 ½  fg
where A0 and A are the absorbances measured for the antibody in
the absence and presence of antigen, respectively, and a0 and i0
respectively the total concentrations of antigen and antibody.
Increasing concentrations (0.5–100 nM) of the VWF fragments
or pVWF with or without being denatured were mixed with a
constant amount of SZ34 (0.3 nM), in 1% (w/v) BSA-PBS,
respectively, until equilibrium were reached (15 h incubation at
22uC). Then the proportion of SZ34 which remained unsaturated
at each concentration of various VWF fragments and pVWF was
measured by an ELISA method as following. The antigen/
antibody complexes were added to the microtiter plates coated
with 100 ml of pVWF (7.5 mg/ml) and incubated at 37uC for 2 h.
After being washed, the wells were incubated at 37uC for 2 h with
HRP-labeled goat anti-mouse IgG (Sigma) in 1% (w/v) BSA-PBS.
The plates were washed 5 times and tetramethyl benzidine (TMB)
solution was added for color development. Absorbance was read at
450 nm and A0 and A were then obtained, respectively.
Binding of SZ34 to native and unfolded VWF by Western
blot/ELISA based on polystyrene microspheres
To distinguish the linear from the conformational epitope of
SZ34, we used an in-house Western blot/ELISA (Western blot in
combination with ELISA) based on polystyrene microspheres.
SZ129 (a mAb to VWF A1 domain) was used as a control. Briefly,
20 mg/ml of SZ34 or SZ129 in 0.05 M sodium carbonate buffer
(pH 9.6) was mixed with 1:10 volume of 50 mg/ml polystyrene
microsphere suspension (SDL37; Takeda Chemical Industries,
Co., Ltd., Osaka, Japan). The mixtures were incubated at room
temperature for 2 h with shaking. The microspheres were then
centrifuged and resuspended in a two-fold dilution of the starting
volume of 2.5% (w/v) BSA-PBS to block the free binding sites.
This solution was incubated at room temperature for 2 h with
constant shaking. After washing three times with PBS, the
microspheres were incubated with 100 nM of pVWF with or
without denaturing at room temperature for 1 h with gentle
agitation. The microspheres were washed three times with PBS,
added in sample buffer (0.0625 M Tris-HCl buffer, pH 6.8, 10%
(v/v) glycerol, 2% (w/v) SDS, 5% (v/v) b-mercaptoethanol,
0.001% (w/v) bromophenol blue, 4 mM EDTA), and then heated
at 99uC for 5 min. After centrifugation at 10,000 g for 3 min, the
supernatants were subjected to 6% SDS-PAGE. The proteins were
transferred to membranes and blotted with HRP-conjugated anti-
VWF IgG (Dako).
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